Logo image of MRUS

MERUS NV (MRUS) Stock Fundamental Analysis

NASDAQ:MRUS - Nasdaq - NL0011606264 - Common Stock - Currency: USD

55.14  +13.54 (+32.55%)

After market: 55.14 0 (0%)

Fundamental Rating

4

MRUS gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. While MRUS has a great health rating, there are worries on its profitability. MRUS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MRUS has reported negative net income.
In the past year MRUS has reported a negative cash flow from operations.
In the past 5 years MRUS always reported negative net income.
MRUS had a negative operating cash flow in each of the past 5 years.
MRUS Yearly Net Income VS EBIT VS OCF VS FCFMRUS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

The Return On Assets of MRUS (-27.51%) is better than 69.52% of its industry peers.
Looking at the Return On Equity, with a value of -33.23%, MRUS is in the better half of the industry, outperforming 75.04% of the companies in the same industry.
Industry RankSector Rank
ROA -27.51%
ROE -33.23%
ROIC N/A
ROA(3y)-32.12%
ROA(5y)-29.6%
ROE(3y)-43.27%
ROE(5y)-46.9%
ROIC(3y)N/A
ROIC(5y)N/A
MRUS Yearly ROA, ROE, ROICMRUS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MRUS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MRUS Yearly Profit, Operating, Gross MarginsMRUS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

More info and screens

8

2. Health

2.1 Basic Checks

MRUS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MRUS has more shares outstanding
The number of shares outstanding for MRUS has been increased compared to 5 years ago.
There is no outstanding debt for MRUS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MRUS Yearly Shares OutstandingMRUS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
MRUS Yearly Total Debt VS Total AssetsMRUS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 10.72 indicates that MRUS is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 10.72, MRUS belongs to the best of the industry, outperforming 88.59% of the companies in the same industry.
There is no outstanding debt for MRUS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 10.72
ROIC/WACCN/A
WACC7.58%
MRUS Yearly LT Debt VS Equity VS FCFMRUS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

MRUS has a Current Ratio of 6.54. This indicates that MRUS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 6.54, MRUS is in the better half of the industry, outperforming 65.95% of the companies in the same industry.
A Quick Ratio of 6.54 indicates that MRUS has no problem at all paying its short term obligations.
MRUS's Quick ratio of 6.54 is fine compared to the rest of the industry. MRUS outperforms 66.31% of its industry peers.
Industry RankSector Rank
Current Ratio 6.54
Quick Ratio 6.54
MRUS Yearly Current Assets VS Current LiabilitesMRUS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for MRUS have decreased strongly by -51.47% in the last year.
MRUS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -17.78%.
The Revenue has been growing slightly by 3.03% on average over the past years.
EPS 1Y (TTM)-51.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-137.29%
Revenue 1Y (TTM)-17.78%
Revenue growth 3Y-9.72%
Revenue growth 5Y3.03%
Sales Q2Q%235.76%

3.2 Future

MRUS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.63% yearly.
The Revenue is expected to grow by 80.39% on average over the next years. This is a very strong growth
EPS Next Y-33.69%
EPS Next 2Y-13.06%
EPS Next 3Y-2.76%
EPS Next 5Y25.63%
Revenue Next Year27.68%
Revenue Next 2Y17.14%
Revenue Next 3Y65.82%
Revenue Next 5Y80.39%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MRUS Yearly Revenue VS EstimatesMRUS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
MRUS Yearly EPS VS EstimatesMRUS Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MRUS. In the last year negative earnings were reported.
Also next year MRUS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRUS Price Earnings VS Forward Price EarningsMRUS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRUS Per share dataMRUS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 8

4.3 Compensation for Growth

A cheap valuation may be justified as MRUS's earnings are expected to decrease with -2.76% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.06%
EPS Next 3Y-2.76%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MRUS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MERUS NV

NASDAQ:MRUS (5/23/2025, 8:37:55 PM)

After market: 55.14 0 (0%)

55.14

+13.54 (+32.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)07-30 2025-07-30/amc
Inst Owners105.59%
Inst Owner Change6.51%
Ins Owners0.57%
Ins Owner Change0.12%
Market Cap3.81B
Analysts87.5
Price Target87.08 (57.93%)
Short Float %8.8%
Short Ratio7.42
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.25%
Min EPS beat(2)-62.2%
Max EPS beat(2)51.7%
EPS beat(4)2
Avg EPS beat(4)3.49%
Min EPS beat(4)-62.2%
Max EPS beat(4)51.7%
EPS beat(8)5
Avg EPS beat(8)7.68%
EPS beat(12)8
Avg EPS beat(12)6.27%
EPS beat(16)10
Avg EPS beat(16)8.08%
Revenue beat(2)1
Avg Revenue beat(2)19.17%
Min Revenue beat(2)-8.95%
Max Revenue beat(2)47.28%
Revenue beat(4)1
Avg Revenue beat(4)0.57%
Min Revenue beat(4)-20.67%
Max Revenue beat(4)47.28%
Revenue beat(8)3
Avg Revenue beat(8)0.05%
Revenue beat(12)6
Avg Revenue beat(12)0.72%
Revenue beat(16)9
Avg Revenue beat(16)1.8%
PT rev (1m)-2.98%
PT rev (3m)-1.87%
EPS NQ rev (1m)-0.16%
EPS NQ rev (3m)-10.02%
EPS NY rev (1m)-1.02%
EPS NY rev (3m)-11.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-10.12%
Revenue NY rev (1m)9.61%
Revenue NY rev (3m)-15.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 105.57
P/FCF N/A
P/OCF N/A
P/B 5.89
P/tB 5.9
EV/EBITDA N/A
EPS(TTM)-4.12
EYN/A
EPS(NY)-4.23
Fwd EYN/A
FCF(TTM)-2.71
FCFYN/A
OCF(TTM)-2.69
OCFYN/A
SpS0.52
BVpS9.37
TBVpS9.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.51%
ROE -33.23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32.12%
ROA(5y)-29.6%
ROE(3y)-43.27%
ROE(5y)-46.9%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 74.06%
Cap/Sales 5.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.54
Quick Ratio 6.54
Altman-Z 10.72
F-Score4
WACC7.58%
ROIC/WACCN/A
Cap/Depr(3y)275.9%
Cap/Depr(5y)195.01%
Cap/Sales(3y)10.83%
Cap/Sales(5y)7.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-51.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-137.29%
EPS Next Y-33.69%
EPS Next 2Y-13.06%
EPS Next 3Y-2.76%
EPS Next 5Y25.63%
Revenue 1Y (TTM)-17.78%
Revenue growth 3Y-9.72%
Revenue growth 5Y3.03%
Sales Q2Q%235.76%
Revenue Next Year27.68%
Revenue Next 2Y17.14%
Revenue Next 3Y65.82%
Revenue Next 5Y80.39%
EBIT growth 1Y-73.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-44.25%
EBIT Next 3Y-4.83%
EBIT Next 5YN/A
FCF growth 1Y-28.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-30.68%
OCF growth 3YN/A
OCF growth 5YN/A